Effects of Torcetrapib in Patients at High Risk for Coronary Events

J. Barter, Philip; J. Caulfield, Mark; Eriksson, Mats; M. Grundy, Scott; J.P. Kastelein, John; Komajda, Michel; López‐Sendón, José; Mosca, Lori; Tardif, Jean‐Claude; D. Waters, David; L. Shear, Charles; H. Revkin, James; A. Buhr, Kevin; R. Fisher, Marian; R. Tall, Alan; Brewer, Bryan

doi:10.1056/nejmoa0706628

Public

Effects of Torcetrapib in Patients at High Risk for Coronary Events

Published in New England Journal of Medicine • Nov 5, 2007

Authors:

Philip J. Barter

Mark J. Caulfield

Mats Eriksson

Abstract

BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an inc...

Subject

Medicine

Internal medicine

Cardiology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!